Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Deals

Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor

Fineline Cube Aug 13, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August...

Company Drug

Sino Biopharmaceutical’s TQB3142 IND Application Accepted by China’s NMPA for Malignant Tumor Treatment

Fineline Cube Aug 13, 2025

Sino Biopharmaceutical Limited (HKG: 1177) announced that the Investigational New Drug (IND) application for TQB3142,...

Company Drug

Novartis’ Leqvio Approved by FDA as Standalone Therapy for Hypercholesterolemia

Fineline Cube Aug 13, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 12, 2025, that the U.S. Food...

Company Deals Drug

HighTide Therapeutics Collaborates with IMB to Assess HTD1801 in T2DM with CKD

Fineline Cube Aug 13, 2025

China-based HighTide Therapeutics, Inc. (HKG: 2511) announced the commencement of a collaborative project with the...

Policy / Regulatory

FDA Launches PreCheck Program to Strengthen U.S. Pharmaceutical Supply Chain

Fineline Cube Aug 13, 2025

The U.S. Food and Drug Administration (FDA) announced the launch of “FDA PreCheck” on August...

Company

Pfizer China Restructures Oncology and Rare Disease Units for Enhanced Focus

Fineline Cube Aug 13, 2025

Pfizer China (NYSE: PFE) announced on August 11, 2025, an organizational optimization of its Oncology and...

Policy / Regulatory

China’s NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List

Fineline Cube Aug 12, 2025

China’s National Healthcare Security Administration (NHSA) released the preliminary formal review results for the 2025...

Company

Legend Biotech Reports Q2 Revenue Growth of 36.7% and H1 Growth of 60.4%

Fineline Cube Aug 12, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) reported unaudited financial statements for the three months (Q2)...

Company

Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition

Fineline Cube Aug 12, 2025

Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) reported financial results for the first quarter of...

Company Drug

Hengrui’s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China’s NMPA

Fineline Cube Aug 12, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025,...

Policy / Regulatory

Macao Drug Administration Expands White List for Designated Medical Institutions in Cooperation Zone

Fineline Cube Aug 12, 2025

The Drug Administration of the Macao Special Administrative Region (SAR) of China has announced the...

Legal / IP

CureVac and GSK Resolve mRNA Vaccine Patent Dispute With BioNTech and Pfizer

Fineline Cube Aug 12, 2025

CureVac N.V. (NASDAQ: CVAC) announced on August 7, 2025, that it has reached an agreement...

Others

Shanghai Moyang Biotechnology Secures Hundreds of Millions in Funding to Expand Global Reach

Fineline Cube Aug 12, 2025

Shanghai Moyang Biotechnology Co., Ltd. announced on August 8, 2025, that it has successfully closed...

Company Drug

Novartis Begins Shipping Next-Gen Anti-VEGF Drug Beovu for Diabetic Macular Edema

Fineline Cube Aug 12, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 11, 2025, the initiation of commercial...

Company Drug

Arvinas and Pfizer’s Vepdegestrant NDA Accepted by FDA for ER+/HER2- Breast Cancer

Fineline Cube Aug 12, 2025

Arvinas, Inc. (NASDAQ: ARVN) and its partner Pfizer (NYSE: PFE) announced on August 8, 2025,...

Company Medical Device

J&J MedTech Gains China Approval for MENTOR MemoryGel Xtra Breast Implants

Fineline Cube Aug 12, 2025

US major Johnson & Johnson MedTech announced that its MENTOR MemoryGel Xtra Breast Implants have...

Company Drug

Mabwell Initiates U.S. Clinical Study of 9MW2821 for Triple-Negative Breast Cancer

Fineline Cube Aug 12, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced the first patient dosing in the...

Company Deals

Fosun Pharma Inks Licensing Pact With Expedition for DPP-1 Inhibitor XH-S004

Fineline Cube Aug 12, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced on August 11, 2025, that...

Company Deals

Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China

Fineline Cube Aug 12, 2025

On August 12, 2025, China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its exclusive...

Company Deals

Biocytogen Partners with Megarobo to Drive Intelligent Upgrading in Antibody R&D

Fineline Cube Aug 12, 2025

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has entered into a...

Posts pagination

1 … 159 160 161 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.